Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 4

CATABASIS Form 4 April 07, 201	S PHARMACEU	JTICALS	INC						
Check thi if no long subject to Section 14 Form 4 or Form 5 obligatior may conti <i>See</i> Instru 1(b).	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940				N OMB Number: Expires: Estimated burden hou response	Number:3235-0287Number:January 31Expires:2005Estimated averageburden hours perresponse0.5			
(Print or Type R	Responses)								
(Last) C/O CATAE PHARMAC) Middle) C., ONE	Symbol CATA PHAR [CATE 3. Date of	MACEUT] of Earliest T Day/Year)	TICALS	-	Issuer (Ch X Director	of Reporting Per eck all applicabl ve title 109 below)	e) % Owner
B14202 (Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
	GE, MA 02139						Person		
(City)		(Zip)					cquired, Disposed		
	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Repo	ort on a separate line	e for each cl	ass of sec	urities benet	Perso	ns who res	or indirectly. spond to the colle ained in this form		SEC 1474 (9-02)

information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 4.8	04/05/2016		А	13,000	<u>(1)</u>	04/04/2026	Common Stock	13,000	

Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 4

Reporting Owners

1

**Signature of Reporting

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
KISHBAUCH MICHAEL D C/O CATABASIS PHARMAC ONE KENDALL SQ., BLDG CAMBRIDGE, MA 02139	· · · · · · · · · · · · · · · · · · ·	Х				
Signatures						
/s/ Michael D. Kishbauch	04/07/2016					

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on April 5, 2016. The option is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversary of the grant date until the third anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.